Ann: Positive interim TACTI-mel data presented at SITC, page-16

C3, howdy mate......Small trials for ph1 (the norm) part- A-18, part B-6......Unlikely to move  the market
much.......The important thing is the safety and the patients acceptance of increased dosages.....Nice tick there
for part A, at this stage part B appears to be headed in the same direction.....If confirmed that will be a big big tick IMO...
My reasons for this thought.....Part-A is developing through 4 cycles of keytruda, part-B commenced at cycle 1....
PH 2 trials need a much bigger trial to be accepted, therefore if Immutep can start ph2 at cycle 1 it should reasonably
be expected that trials will give quicker results thus limiting costs also if these ph2 follow on from ph1 indications
there is every chance of fast tracking approval.......Leave the market out of this mate, let the traders play this out
tomorrow and see what happens the day after....